Journal article
Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis
Lancet neurology, Vol.19(6), pp.502-512
06/2020
DOI: 10.1016/S1474-4422(20)30143-5
PMID: 32470422
Abstract
Background
Disease-modifying treatments are in development for Huntington's disease; crucial to their success is to identify a timepoint in a patient's life when there is a measurable biomarker of early neurodegeneration while clinical function is still intact. We aimed to identify this timepoint in a novel cohort of young adult premanifest Huntington's disease gene carriers (preHD) far from predicted clinical symptom onset.
Details
- Title: Subtitle
- Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis
- Creators
- Rachael I Scahill - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKPaul Zeun - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKKatherine Osborne-Crowley - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKEileanoir B Johnson - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKSarah Gregory - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKChristopher Parker - Department of Computer Science and Centre for Medical Image Computing, University College London, London, UKJessica Lowe - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKAkshay Nair - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKClaire O'Callaghan - Department of Psychiatry and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UKChristelle Langley - Department of Psychiatry and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UKMarina Papoutsi - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKPeter McColgan - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKCarlos Estevez-Fraga - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKKate Fayer - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKHenny Wellington - Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UKFilipe B Rodrigues - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKLauren M Byrne - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKAmanda Heselgrave - Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UKHarpreet Hyare - Department of Brain Repair and Rehabilitation, University College London Institute of Neurology, London, UKCristina Sampaio - CHDI Foundation, Princeton, NJ, USAHenrik Zetterberg - Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UKHui Zhang - University College LondonEdward J Wild - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UKGeraint Rees - University College London Institute of Cognitive Neuroscience, University College London, London, UKTrevor W Robbins - Department of Psychology and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UKBarbara J Sahakian - Department of Psychiatry and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UKDouglas Langbehn - University of Iowa, PsychiatrySarah J Tabrizi - Huntington's Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London, London, UK
- Resource Type
- Journal article
- Publication Details
- Lancet neurology, Vol.19(6), pp.502-512
- DOI
- 10.1016/S1474-4422(20)30143-5
- PMID
- 32470422
- NLM abbreviation
- Lancet Neurol
- ISSN
- 1474-4422
- eISSN
- 1474-4465
- Publisher
- Lancet Pub. Group
- Language
- English
- Date published
- 06/2020
- Academic Unit
- Psychiatry; Iowa Neuroscience Institute
- Record Identifier
- 9984066384202771
Metrics
41 Record Views